Nurix Therapeutics Inc
For the period ended Nov 30, 2023. Filed Feb 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 15, 2024
NRIX$16.14+5.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| November 30, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $54,627 | $64,474 |
| Marketable securities, current | 233,281 | 244,667 |
| Prepaid expenses and other current assets | 7,595 | 9,308 |
| Total current assets | 295,503 | 318,449 |
| Marketable securities, non-current | 7,421 | 63,879 |
| Operating lease right-of-use assets | 31,142 | 12,345 |
| Property and equipment, net | 16,808 | 17,163 |
| Restricted cash | 901 | 901 |
| Other assets | 3,823 | 4,022 |
| Total assets | $355,598 | $416,759 |
| Liabilities and stockholdersʼ equity | ||
| Current liabilities: | ||
| Accounts payable | $6,401 | $5,064 |
| Accrued expenses and other current liabilities | 24,970 | 22,428 |
| Operating lease liabilities, current | 7,489 | 5,530 |
| Deferred revenue, current | 48,098 | 37,633 |
| Total current liabilities | 86,958 | 70,655 |
| Operating lease liabilities, net of current portion | 23,125 | 6,434 |
| Deferred revenue, net of current portion | 45,022 | 35,974 |
| Total liabilities | 155,105 | 113,063 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value— 10,000,000 shares authorized as of November 30, 2023 and 2022; no shares issued and outstanding as of November 30, 2023 and 2022 | — | — |
| Common stock, $0.001 par value— 500,000,000 shares authorized as of November 30, 2023 and 2022; 48,718,552 and 47,172,299 shares issued and outstanding as of November 30, 2023 and 2022, respectively | 49 | 47 |
| Additional paid-in capital | 746,299 | 709,220 |
| Accumulated other comprehensive loss | (655) | (4,319) |
| Accumulated deficit | (545,200) | (401,252) |
| Total stockholders’ equity | 200,493 | 303,696 |
| Total liabilities and stockholders’ equity | $355,598 | $416,759 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.